Literature DB >> 33668805

Multi-Omics Data Analysis of Gene Expressions and Alterations, Cancer-Associated Fibroblast and Immune Infiltrations, Reveals the Onco-Immune Prognostic Relevance of STAT3/CDK2/4/6 in Human Malignancies.

Bashir Lawal1,2, Li-Ching Lin3, Jih-Chin Lee4, Jia-Hong Chen5, Tanios S Bekaii-Saab6, Alexander T H Wu7,8,9, Ching-Liang Ho5.   

Abstract

Signal transducer and activator of transcription 3 (STAT3)/Cyclin-dependent kinases are multifunctional proteins that play an important implicative role in cancer initiations, progression, drug resistance, and metastasis, and has been extensively explored in cancer therapy. However, the genetic alterations of STAT3/CDK2/4/6 and its role in predicting immune infiltration and immunotherapeutic response are yet to be well exploited. In this study, we use in silico methods to analyze differential expression, prognostic value, genetic and epigenetic alterations, association with tumor-infiltrating immune cells, and cancer-associated fibroblast (CAF) infiltrations of STAT3/CDK2/4/6 in multiple cancer types. Our results revealed that the expression of STAT3/CDK2/4/6 was altered in various cancers and is associated with poor overall and disease-free survival of the cohorts. Moreover, genetic alterations in STAT3/CDK2/4/6 co-occurred with a number of other genetic alterations and are associated with poorer prognoses of the cohorts. The protein-protein interaction (PPI) network analysis suggests CDK2/4/6/STAT3 may directly interact with factors that promote tumorigenesis and immune response. We found that STAT3/CDK2/4/6 expressions were associated with infiltrations of CAF and the various immune cells in multiple cancers and it's associated with poor response to immunotherapy. Collectively, our study suggested that STAT3/CDK2/4/6 are important onco-immune signatures that play central roles in tumor immune invasion, poor prognoses and, immune therapy response. Findings from the present study may therefore be clinically useful in prognosis assessment and follow-up management of immunotherapy.

Entities:  

Keywords:  cancer-associated fibroblast infiltration; cyclin-dependent kinases; genetic alterations; signal transducer and activator of transcription 3; tumor immune infiltrations

Year:  2021        PMID: 33668805     DOI: 10.3390/cancers13050954

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  13 in total

Review 1.  The Trinity: Interplay among Cancer Cells, Fibroblasts, and Immune Cells in Pancreatic Cancer and Implication of CD8+ T Cell-Orientated Therapy.

Authors:  Yu-Hsuan Hung; Li-Tzong Chen; Wen-Chun Hung
Journal:  Biomedicines       Date:  2022-04-18

2.  Identification of DPP4/CTNNB1/MET as a Theranostic Signature of Thyroid Cancer and Evaluation of the Therapeutic Potential of Sitagliptin.

Authors:  Sheng-Yao Cheng; Alexander T H Wu; Gaber El-Saber Batiha; Ching-Liang Ho; Jih-Chin Lee; Halimat Yusuf Lukman; Mohammed Alorabi; Abdullah N AlRasheedi; Jia-Hong Chen
Journal:  Biology (Basel)       Date:  2022-02-17

3.  Leveraging Bulk and Single-Cell RNA Sequencing Data of NSCLC Tumor Microenvironment and Therapeutic Potential of NLOC-15A, A Novel Multi-Target Small Molecule.

Authors:  Bashir Lawal; Alexander T H Wu; Hsu-Shan Huang
Journal:  Front Immunol       Date:  2022-05-17       Impact factor: 8.786

4.  SOCS3 Acts as an Onco-immunological Biomarker With Value in Assessing the Tumor Microenvironment, Pathological Staging, Histological Subtypes, Therapeutic Effect, and Prognoses of Several Types of Cancer.

Authors:  Lirui Dai; Yiran Tao; Zimin Shi; Wulong Liang; Weihua Hu; Zhe Xing; Shaolong Zhou; Xuyang Guo; Xudong Fu; Xinjun Wang
Journal:  Front Oncol       Date:  2022-05-06       Impact factor: 5.738

5.  mTOR/EGFR/iNOS/MAP2K1/FGFR/TGFB1 Are Druggable Candidates for N-(2,4-Difluorophenyl)-2',4'-Difluoro-4-Hydroxybiphenyl-3-Carboxamide (NSC765598), With Consequent Anticancer Implications.

Authors:  Bashir Lawal; Ching-Yu Lee; Ntlotlang Mokgautsi; Maryam Rachmawati Sumitra; Harshita Khedkar; Alexander T H Wu; Hsu-Shan Huang
Journal:  Front Oncol       Date:  2021-03-26       Impact factor: 6.244

6.  MIKB: A manually curated and comprehensive knowledge base for myocardial infarction.

Authors:  Chaoying Zhan; Yingbo Zhang; Xingyun Liu; Rongrong Wu; Ke Zhang; Wenjing Shi; Li Shen; Ke Shen; Xuemeng Fan; Fei Ye; Bairong Shen
Journal:  Comput Struct Biotechnol J       Date:  2021-11-16       Impact factor: 7.271

7.  BC-N102 suppress breast cancer tumorigenesis by interfering with cell cycle regulatory proteins and hormonal signaling, and induction of time-course arrest of cell cycle at G1/G0 phase.

Authors:  Bashir Lawal; Yu-Cheng Kuo; Alexander T H Wu; Hsu-Shan Huang
Journal:  Int J Biol Sci       Date:  2021-07-25       Impact factor: 6.580

8.  Transcriptomic-Based Identification of the Immuno-Oncogenic Signature of Cholangiocarcinoma for HLC-018 Multi-Target Therapy Exploration.

Authors:  Bashir Lawal; Yu-Cheng Kuo; Sung-Ling Tang; Feng-Cheng Liu; Alexander T H Wu; Hung-Yun Lin; Hsu-Shan Huang
Journal:  Cells       Date:  2021-10-25       Impact factor: 6.600

9.  Identification of a Novel Theranostic Signature of Metabolic and Immune-Inflammatory Dysregulation in Myocardial Infarction, and the Potential Therapeutic Properties of Ovatodiolide, a Diterpenoid Derivative.

Authors:  Alexander T H Wu; Bashir Lawal; Yew-Min Tzeng; Chun-Che Shih; Chun-Ming Shih
Journal:  Int J Mol Sci       Date:  2022-01-24       Impact factor: 5.923

10.  In-Silico Evaluation of Genetic Alterations in Ovarian Carcinoma and Therapeutic Efficacy of NSC777201, as a Novel Multi-Target Agent for TTK, NEK2, and CDK1.

Authors:  Harshita Nivrutti Khedkar; Yu-Chi Wang; Vijesh Kumar Yadav; Prateeti Srivastava; Bashir Lawal; Ntlotlang Mokgautsi; Maryam Rachmawati Sumitra; Alexander T H Wu; Hsu-Shan Huang
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.